Brian J. Day, PhD

Special Interests

Research Interests

Cystic Fibrosis, COPD, chronic beryllium disease, interstitial lung disease, sulfur mustard lung injury, drug development. Adaptive glutathione responses to cigarette smoke in COPD. (NIH RO1 HL084469-05) (Primary Investigator). Novel Antioxidant Therapeutics for Sulfur Mustard Toxicity. (NIH U54 ES015678-06) (Project 2 Leader). Modulation of lung inflammation by CFTR-dependent thiols. (Cystic Fibrosis Foundation Research Grant) (Primary Investigator). Targeting oxidative stress in chronic beryllium disease.(NIH RO1 ES017582-04) (Multiple Primary Investigator).

Awards & Recognition

Basic Sciences Section Head, Department of Medicine, National Jewish Health
Chief Science Officer, Aeolus Pharmaceuticals
Chairman, Board of Publications Committee, Mechanisms Specialty Section Councilor, Society of Toxicology
NIH Study Section Member, LIRR

Professional Memberships

Publications

Dobis, D.R., Sawyer R.T., Gillespie M.M., Huang J., Newman L.S., Maier L.A. and Day B.J. Modulation of Lymphocyte Proliferation by Antioxidants in Chronic Beryllium Disease. Am. J. Respir. Crit. Care Med. 177:1002-1011, 2008.

Day, B.J. Antioxidants as potential therapeutics for lung fibrosis. Antiox Redox Sig,10:355-370, 2008.

Kachadourian, R and Day, B.J. Flavonoid-induced glutathione depletion: potential implications for cancer treatment. Free Radic. Biol. Med. 41:65-76, 2006.

Velsor, L.W., Kariya C.,Kachadourian, R., and Day, B.J. Mitochondrial oxidative stress in the lungs of cystic fibrosis transmembrane conductance regulator protein mutant mice. Am. J. Respir. Cell Mol. Biol. 35:579-586, 2006.

Day BJ, van Heeckeren AM, Min E, and Velsor L. Role for CFTR in a glutathione response to bronchopulmonary pseudomonas infection. Infect Immun 72:2045-2051, 2004.

Academic Affiliations

Professor of Medicine, Pharmaceutical Sciences and Immunology, University of Colorado Denver
Professor, Colorado School of Public Health, University of Colorado Denver

Conflicts of Interest

National Jewish Health physicians and scientists may collaborate with pharmaceutical or other industries to develop medical and scientific breakthroughs or to provide education on trends in quality medical practice and outcomes to physicians and health professionals around the country. National Jewish Health maintains a strict conflict of interest policy to ensure that all potential conflicts are clearly visible and that management plans are put in place in order to further innovation and education while ensuring the protection of our patients and the integrity of our research. National Jewish Health publicly discloses any payment to our physicians or scientists. View this faculty member’s industry relationships and collaborations.